Literature DB >> 16415921

A marker for Stevens-Johnson syndrome ...: ethnicity matters.

C Lonjou1, L Thomas, N Borot, N Ledger, C de Toma, H LeLouet, E Graf, M Schumacher, A Hovnanian, M Mockenhaupt, J-C Roujeau.   

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but severe cutaneous adverse drug reactions, which can be caused by a certain number of specific drugs among which is carbamazepine, an antiepileptic agent. A very strong association of carbamazepine-induced SJS with HLA-B*1502 has recently been described in the Han Chinese population. Here in, we report preliminary results from a European study (RegiSCAR) of 12 carbamazepine-induced SJS/TEN cases (nine French and three German). Among these only four had a HLA-B*1502 allele. Remarkably, these four patients had an Asian ancestry, whereas the others did not as far as we have ascertained. This shows that although the HLA region may contain important genes for SJS, the HLA-B*1502 allele is not a universal marker for this disease and that ethnicity matters.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16415921     DOI: 10.1038/sj.tpj.6500356

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  74 in total

1.  Problems with the collection and interpretation of Asian-American health data: omission, aggregation, and extrapolation.

Authors:  Ariel T Holland; Latha P Palaniappan
Journal:  Ann Epidemiol       Date:  2012-06       Impact factor: 3.797

2.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome.

Authors:  Sonal Choudhary; Michael McLeod; Daniele Torchia; Paolo Romanelli
Journal:  J Clin Aesthet Dermatol       Date:  2013-06

3.  [Ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis].

Authors:  Argyrios Chronopoulos; Maja Mockenhaupt; Uwe Pleyer
Journal:  Ophthalmologe       Date:  2021-03-16       Impact factor: 1.059

4.  HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.

Authors:  Mark McCormack; Ana Alfirevic; Stephane Bourgeois; John J Farrell; Dalia Kasperavičiūtė; Mary Carrington; Graeme J Sills; Tony Marson; Xiaoming Jia; Paul I W de Bakker; Krishna Chinthapalli; Mariam Molokhia; Michael R Johnson; Gerard D O'Connor; Elijah Chaila; Saud Alhusaini; Kevin V Shianna; Rodney A Radtke; Erin L Heinzen; Nicole Walley; Massimo Pandolfo; Werner Pichler; B Kevin Park; Chantal Depondt; Sanjay M Sisodiya; David B Goldstein; Panos Deloukas; Norman Delanty; Gianpiero L Cavalleri; Munir Pirmohamed
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

5.  Ethnicity and adverse drug reactions.

Authors:  Erik Eliasson
Journal:  BMJ       Date:  2006-05-20

Review 6.  HapMap, pharmacogenomics, and the goal of personalized prescribing.

Authors:  Kevin M O'Shaughnessy
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

7.  [Not Available].

Authors:  Josiane Bégin; Marianne Guay; Stéphanie Ricard; Maxime Doré; Anne-Marie Mansour
Journal:  Can Pharm J (Ott)       Date:  2013-09

8.  Identification of Stevens-Johnson syndrome and toxic epidermal necrolysis in electronic health record databases.

Authors:  Robert L Davis; Mia A Gallagher; Maryam M Asgari; Melody J Eide; David J Margolis; Eric Macy; James K Burmester; Nandini Selvam; Joseph A Boscarino; Lee F Cromwell; Heather S Feigelson; Jennifer L Kuntz; Pamala A Pawloski; Robert B Penfold; Marsha A Raebel; Gayathri Sridhar; Ann Wu; Lois A La Grenade; Michael A Pacanowski; Simone P Pinheiro
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-04-24       Impact factor: 2.890

9.  Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.

Authors:  Yogita Ghodke Puranik; Angela K Birnbaum; Susan E Marino; Ghada Ahmed; James C Cloyd; Rory P Remmel; Ilo E Leppik; Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2013-01       Impact factor: 2.533

10.  Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.

Authors:  P Brent Ferrell; Howard L McLeod
Journal:  Pharmacogenomics       Date:  2008-10       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.